SGN-30
As of the edition of 20 October 2026, SGN-30 is a drug: stopped in 2010; acts on TNFRSF8.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2010
- Kind
- Unknown
- Registered trials
- 4, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of SGN-30.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFRSF8 | Tumor necrosis factor receptor superfamily member 8 | P28908 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 3 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2004 to now |